Genmab As Stock Return On Asset
GNMSF Stock | USD 298.55 4.07 1.34% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Pink Sheet. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS pink sheet.
Genmab |
Genmab AS Company Return On Asset Analysis
Genmab AS's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Genmab AS Return On Asset | 0.1 |
Most of Genmab AS's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition |
Based on the latest financial disclosure, Genmab AS has a Return On Asset of 0.1029. This is 101.18% lower than that of the Healthcare sector and 100.44% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 173.5% lower than that of the firm.
Genmab Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in return on asset category among related companies.
Genmab Fundamentals
Return On Equity | 0.24 | |||
Return On Asset | 0.1 | |||
Profit Margin | 0.47 % | |||
Operating Margin | 0.38 % | |||
Current Valuation | 26.41 B | |||
Shares Outstanding | 65.96 M | |||
Shares Owned By Institutions | 49.90 % | |||
Price To Earning | 39.08 X | |||
Price To Book | 7.94 X | |||
Price To Sales | 2.45 X | |||
Revenue | 8.48 B | |||
Gross Profit | 8.48 B | |||
EBITDA | 4.24 B | |||
Net Income | 3.01 B | |||
Cash And Equivalents | 21.61 B | |||
Cash Per Share | 330.53 X | |||
Total Debt | 634 M | |||
Debt To Equity | 0.03 % | |||
Current Ratio | 13.11 X | |||
Book Value Per Share | 408.67 X | |||
Cash Flow From Operations | 2.23 B | |||
Earnings Per Share | 12.00 X | |||
Price To Earnings To Growth | 1.20 X | |||
Target Price | 383.57 | |||
Number Of Employees | 1.56 K | |||
Beta | 0.67 | |||
Market Capitalization | 26.78 B | |||
Total Asset | 24.63 B | |||
Retained Earnings | (3.96 B) | |||
Working Capital | 3.72 B | |||
Current Asset | 4.14 B | |||
Current Liabilities | 419 M | |||
Z Score | 25.2 | |||
Net Asset | 24.63 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Genmab Pink Sheet please use our How to Invest in Genmab AS guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |